Wuzi Yanzong Pill relieves MPTP-induced motor dysfunction and neuron loss by inhibiting NLRP3 inflammasome-mediated neuroinflammation
Abstract Parkinson disease (PD) is an age-related neurodegenerative disease, which is associated with the loss of dopaminergic neurons (DA neurons) in the substantia nigra pars compacta (SNpc), and neuroinflammation may lead to the occurrence of PD. Wuzi Yanzong Pill (WYP) has demonstrated neuroprotective and anti-inflammatory properties, but its molecular mechanism of action is still unclear. In this study, we used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice and LPS-mediated BV2 microglia to explore WYP intervention, anti-inflammatory effect and molecular mechanism in vivo and in vitro. The results showed that oral administration of WYP in MPTP-induced PD mice for 2 weeks ameliorated abnormal motor dysfunction, attenuated the loss of TH + neurons in SNpc, protected dopaminergic neurons, and inhibited the activation of microglia in MPTP-induced PD mice and LPS-stimulated BV2 cell. Meanwhile, WYP intervention inhibited the expression of IL-6, TNF-α, Pro-IL-1β, IL-1β, Pro-IL-18, IL-18 and enhanced the expression of IL-10 in the SNpc of PD mice. Simultaneously, WYP intervention inhibited the expression of NLRP3 inflammasome, accompanied by the decrease of the TLR4/MyD88/NF-κB pathway. However, the exact target and interaction of WYP on NLRP3 inflammasome and TLR4/MyD88/NF-κB pathway still needs to be further investigated..
Highlights WYP treatment increased the number of DA neurons in SNpc, improved the behavioral performance of MPTP-induced PD mice, and inhibited the activation of microglia and astrocytes. WYP inhibits inflammatory factors in PD mice and BV2 cells. WYP intervention inhibits NLRP3 inflammasome expression while decreasing TLR4/MyD88/NF-κB pathway..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Metabolic brain disease - 38(2023), 7 vom: 20. Juli, Seite 2211-2222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pan, Tao [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Microglia |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11011-023-01266-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2145570608 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2145570608 | ||
| 003 | DE-627 | ||
| 005 | 20240118105434.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11011-023-01266-8 |2 doi | |
| 035 | |a (DE-627)OLC2145570608 | ||
| 035 | |a (DE-He213)s11011-023-01266-8-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00$jMedizin: Allgemeines |2 bkl | ||
| 100 | 1 | |a Pan, Tao |e verfasserin |0 (orcid)0000-0003-1736-214X |4 aut | |
| 245 | 1 | 0 | |a Wuzi Yanzong Pill relieves MPTP-induced motor dysfunction and neuron loss by inhibiting NLRP3 inflammasome-mediated neuroinflammation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Parkinson disease (PD) is an age-related neurodegenerative disease, which is associated with the loss of dopaminergic neurons (DA neurons) in the substantia nigra pars compacta (SNpc), and neuroinflammation may lead to the occurrence of PD. Wuzi Yanzong Pill (WYP) has demonstrated neuroprotective and anti-inflammatory properties, but its molecular mechanism of action is still unclear. In this study, we used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice and LPS-mediated BV2 microglia to explore WYP intervention, anti-inflammatory effect and molecular mechanism in vivo and in vitro. The results showed that oral administration of WYP in MPTP-induced PD mice for 2 weeks ameliorated abnormal motor dysfunction, attenuated the loss of TH + neurons in SNpc, protected dopaminergic neurons, and inhibited the activation of microglia in MPTP-induced PD mice and LPS-stimulated BV2 cell. Meanwhile, WYP intervention inhibited the expression of IL-6, TNF-α, Pro-IL-1β, IL-1β, Pro-IL-18, IL-18 and enhanced the expression of IL-10 in the SNpc of PD mice. Simultaneously, WYP intervention inhibited the expression of NLRP3 inflammasome, accompanied by the decrease of the TLR4/MyD88/NF-κB pathway. However, the exact target and interaction of WYP on NLRP3 inflammasome and TLR4/MyD88/NF-κB pathway still needs to be further investigated. | ||
| 520 | |a Highlights WYP treatment increased the number of DA neurons in SNpc, improved the behavioral performance of MPTP-induced PD mice, and inhibited the activation of microglia and astrocytes. WYP inhibits inflammatory factors in PD mice and BV2 cells. WYP intervention inhibits NLRP3 inflammasome expression while decreasing TLR4/MyD88/NF-κB pathway. | ||
| 650 | 4 | |a Parkinson disease | |
| 650 | 4 | |a Wuzi Yanzong Pill | |
| 650 | 4 | |a Microglia | |
| 650 | 4 | |a NLRP3 inflammasome | |
| 700 | 1 | |a Xiao, Qi |0 (orcid)0009-0007-2074-8744 |4 aut | |
| 700 | 1 | |a Fan, Hui-Jie |0 (orcid)0000-0001-8543-1368 |4 aut | |
| 700 | 1 | |a Xu, Lei |0 (orcid)0000-0002-7055-7774 |4 aut | |
| 700 | 1 | |a Qin, Shao-Chen |0 (orcid)0009-0005-6237-212X |4 aut | |
| 700 | 1 | |a Yang, Li-Xia |0 (orcid)0009-0002-7917-7302 |4 aut | |
| 700 | 1 | |a Jin, Xiao-ming |0 (orcid)0000-0002-8671-8640 |4 aut | |
| 700 | 1 | |a Xiao, Bao-Guo |0 (orcid)0000-0003-3335-8992 |4 aut | |
| 700 | 1 | |a Zhang, Bo |0 (orcid)0009-0000-9168-1005 |4 aut | |
| 700 | 1 | |a Ma, Cun-Gen |0 (orcid)0000-0001-7055-4912 |4 aut | |
| 700 | 1 | |a Chai, Zhi |0 (orcid)0000-0002-7464-5384 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Metabolic brain disease |d Springer US, 1986 |g 38(2023), 7 vom: 20. Juli, Seite 2211-2222 |w (DE-627)168086751 |w (DE-600)632824-6 |w (DE-576)518182371 |x 0885-7490 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:7 |g day:20 |g month:07 |g pages:2211-2222 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11011-023-01266-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.00$jMedizin: Allgemeines |q VZ |0 106409646 |0 (DE-625)106409646 |
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 7 |b 20 |c 07 |h 2211-2222 | ||